HMN 2025: How Combination remedy extends survival in superior pores and skin cancer, trial finds

In sufferers with a sophisticated kind of pores and skin cancer referred to as cutaneous squamous cell carcinoma (cSCC), those that acquired the mixture of the immunotherapy drug avelumab and focused agent cetuximab had nearly 4 occasions longer median progression-free survival in comparison with sufferers who acquired avelumab alone, in accordance with the outcomes of a part 2 trial introduced at present on the American Society of Clinical Oncology (ASCO) assembly and concurrently printed within the Journal of Clinical Oncology.

“It is each an honor and humbling to develop scientific trials that may be potential choices for our sufferers,” stated lead creator and study chair for the trial, Dan Zandberg, M.D., affiliate professor of drugs on the University of Pittsburgh and medical oncology co-leader of the pinnacle and neck cancer program at UPMC Hillman Cancer Center. “My hope is that the insights we made with this trial will result in extra research that may finally carry a brand new immunotherapy-based mixture into customary of take care of sufferers with superior cSCC.”

cSCC is a typical kind of pores and skin cancer with about 1.8 million instances identified within the U.S. annually. About 95% of cSCCs are detected early and might be handled with minor surgical procedure. But in uncommon instances, sufferers will go on to develop superior cSCC, which incorporates regionally superior tumors that can’t be surgically eliminated and metastatic illness. At this mark, the prognosis is poor and remedy is targeted on extending survival, not remedy.

Zandberg developed the Alliance A091802 (NCT03944941) part 2 trial in collaboration with the Alliance for Clinical Trials in Oncology by the National Cancer Institute’s (NCI) National Clinical Trials Network.

This trial, which was open nationwide, included 57 sufferers with superior cSCC. UPMC Hillman was the main web site for affected person recruitment, with a few of these sufferers recruited and handled at its community of greater than 70 group cancer facilities.

Twenty-nine sufferers acquired avelumab and cetuximab and 28 acquired avelumab alone. Because the trial had a crossover design, 9 sufferers within the avelumab group whose cancer progressed switched to the mixture group.

Avelumab is an immune checkpoint inhibitor drug that targets a protein discovered on cancer cells referred to as PD-L1. When PD-L1 binds to a receptor on T cells referred to as PD-1, it acts like a brake, slowing down the cancer-killing exercise of T cells. Avelumab and different anti-PD-1/PD-L1 therapies launch these brakes.

Cetuximab is a monoclonal antibody that targets EGFR (epidermal development issue receptor), a protein that performs a essential function in tumor cell development, proliferation and survival and which is usually present in excessive ranges on cSCC cells. It prompts pure killer cells, which assist battle tumors, and may also activate dendritic cells, which might then stimulate T cells. Previous research achieved at UPMC Hillman by Robert Ferris, M.D., Ph.D. and his lab helped reveal cetuximab’s impact on the immune system.

“The rationale for the mixture is that avelumab and different anti-PD-1/PD-L1 therapies have been proven to take the foot off the brake of the immune system, whereas cetuximab is urgent on the gasoline pedal—making an attempt to work collectively to make the immune system go quicker and assault the tumor,” stated Zandberg. “What’s thrilling is that on this trial the efficacy of the mixture means that the 2 medication have been synergistic, reasonably than simply additive.”

The study confirmed that the first endpoint of progression-free survival was considerably larger in sufferers who acquired avelumab plus cetuximab with a median of 11 months in comparison with simply 3 months in sufferers who acquired avelumab alone.

Even although avelumab and cetuximab led to an nearly quadrupling of median progression-free survival in comparison with avelumab alone, the trial doesn’t help this mix as an ordinary remedy for sufferers. That’s as a result of for the reason that trial was launched, two different anti-PD-1/PD-L1 therapies—cemiplimab and pembrolizumab—have been authorised and had larger efficacy than avelumab in trials in sufferers with cSCC.

However, the trial represents the primary accomplished potential randomized comparability of cetuximab plus blockade of the PD-1/PD-L1 pathway versus blockade of that pathway alone in cSCC or head and neck cancer, where this mix has additionally proven promise. The trial supplies worthwhile data for future trials.

“These findings spotlight the potential advantages of mixing cetuximab with an anti-PD-1/PD-L1 remedy and factors to the significance of extra scientific trials combining both customary of care pembrolizumab or cemiplimab with cetuximab as a possible approach to enhance affected person outcomes in superior cSCC,” stated Zandberg.

Notably, sufferers within the crossover arm had the same progression-free survival to those that acquired the mixture from the beginning. Currently, if a affected person fails immunotherapy with pembrolizumab or cemiplimab, they swap to cetuximab or chemotherapy. But this trial means that persevering with immunotherapy and including cetuximab may very well be extra helpful.